Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Innovations study located that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://edwarde435olu1.shopping-wiki.com/user